Bristol Myers Squibb 3y Report this post Today our CEO, Giovanni Caforio, becomes chairman of the PhRMA board of directors and will play a leading role in the global dialogue on healthcare, patient access and delivering innovative medicines to treat the world's most challenging diseases. Positive topline results from the Phase 3 KarMMa-3 trial showed treatment with Abecma compared to standard combination regimens in adults with relapsed and refractory multiple myeloma after two to four prior lines of therapy and refractory to the last regimen met its primary endpoint of demonstrating a statistically significant improvement in progression-free survival. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods, including amortization of acquired intangible assets, including product rights that generate a significant portion of our ongoing revenue and will recur until the intangible assets are fully amortized, unwind of inventory purchase price adjustments, acquisition and integration expenses, restructuring costs, accelerated depreciation and impairment of property, plant and equipment and intangible assets, divestiture gains or losses, stock compensation resulting from accelerated vesting of Celgene awards, certain retention-related employee compensation charges related to the Celgene transaction, pension, legal and other contractual settlement charges, equity investment and contingent value rights fair value adjustments (including fair value adjustments attributed to limited partnership equity method investments) and amortization of fair value adjustments of debt acquired from Celgene in our 2019 exchange offer, among other items. Beginning with the first quarter of 2022, significant R&D charges or other income resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights are no longer excluded from non-GAAP results. Bristol Myers Squibb Announces Positive Topline Results of Phase 3 In 2022, Eliquis passed Revlimid to become Bristol Myers' top-selling product. "Our teams continue to progress our pipeline and achieve significant regulatory and clinical milestones, including the approval of Sotyktu, a first-in-class, TYK2 inhibitor, to treat moderate to severe plaque psoriasis. Environmental, Social & Governance Highlights - Bristol Myers Squibb $ amounts in millions, except per share amounts. Treatment with Abecma also showed an improvement in the key secondary endpoint of overall response rate compared to standard regimens. Bristol Myers Squibb has been in operation in Ireland since 1964, employing over 650 people across a range of activities and business units. 29 min read Reports Third Quarter Revenues of $11.2 Billion Delivers Strong Revenue. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures for a particular quarterly period are available on the companys website at www.bms.com., Risk Evaluation and Mitigation Strategies (REMS), Pre-Approval Access to Investigational Medicines, Areas of Interest & Competitive Research Grants, The Thomas O. Daniel Research Incubator and Collaboration Center, Acquisition FAQs for Celgene Shareholders, Acquisition-related information for Celgene shareholders, Unsubscribe to News Email Alerts - Bristol Myers Squibb, Subscribe to New Email Alerts - Bristol Myers Squibb, BMS at June 2022 oncology and hematology congresses, Committed to creating a better future for cancer patients, People & Business Resource Groups leadership team, Our Commitment to Equal Employment Opportunity, Access to Medicines in the Developing World, UK-CA Slavery and Human Trafficking Statement (PDF), Our Commitment to Global Inclusion & Diversity>. The trial was conducted with 2seventy bio (NASDAQ: TSVT). Phase 2 AXIOMATIC-SSP trial showed that milvexian had an approximate 30% relative risk reduction in recurrent symptomatic ischemic strokes (accepted regulatory endpoint) and favorable safety profile in three arms compared to placebo when used in combination with background dual antiplatelet therapy in patients with an acute non-cardioembolic ischemic stroke or transient ischemic attack. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com. (b) Recent LOE Products includes products with significant expected decline in revenue from a prior reporting period as a result of a loss of exclusivity. U.S. revenues were $1.2 billion compared to $1.1 billion in the prior year period, representing an increase of 17% driven by higher demand across multiple indications, including Opdivo plus Yervoy-based combinations for non-small cell lung cancer, Opdivo plus Cabometyx combination for kidney cancer, and Opdivo-based therapies for various gastric, bladder and esophageal cancers, partially offset by declining second-line eligibility across tumors and increased competition. Findings from clinical, patient-reported outcomes and . 1Acquired IPRD refers to certain in-process research and development (Acquired IPRD) charges resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights. Bristol Myers Squibb 1,079,782 followers 5mo . Bristol Myers Squibb revenue for the quarter ending September 30, 2022 was $11.218B, a 3.49% decline year-over-year. The information contained on, or that may be accessed through, our website or social media channels are not incorporated by reference into, and are not a part of, this document. Our nine new product launches over the last three years including three first-in-class launches this year, combined with progress in our robust and diverse product pipeline, have built a strong foundation for our company. In discussing financial results and guidance, the company refers to financial measures that are not in accordance with U.S. Generally Accepted Accounting Principles (GAAP). November 09, 2022. "We continue to execute against our strategic priorities, deliver solid revenue and earnings growth and advance our product pipeline," said Giovanni Caforio . To learn more about our priorities and goals, please visit our latest ESG report. FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2022 AND 2021. Security and Exchange Commission filings for BRISTOL MYERS SQUIBB CO (BMY) Companies; Documents; Forms; Alerts; Stock Ticker Lookup. Bristol Myers Squibb 2022: The new normal - Invesbrain These statements may be identified by the fact they use words such as should, could, expect, anticipate, estimate, target, may, project, guidance, intend, plan, believe, will and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. These R&D charges that were previously specified are now presented in a new financial statement line item labeled Acquired IPRD. Forward-looking statements in this earnings release should be evaluated together with the many risks and uncertainties that affect the companys business and market, particularly those identified in the cautionary statement and risk factors discussion in the companys Annual Report on Form 10-K for the year ended December 31, 2021, as updated by the companys subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. In 2021, the Bristol Myers Squibb Foundation (BMSF), with its partners, National Medical Fellowships and the American Association for Cancer Research, began training the first group of 52 physicians selected for its Diversity in Clinical Trials Career Development Program (BMSF DCTCDP). These statements may be identified by the fact they use words such as should, could, expect, anticipate, estimate, target, may, project, guidance, intend, plan, believe, will and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. Select Bristol Myers Squibb and Bristol Myers Squibb-Pfizer Alliance studies at the AHA Annual Scientific Sessions 2022 include: . Bristol-Myers Squibb Reports Q4 and Full Year Results for 2019 The FDA assigned a PDUFA goal date of June 24, 2022. Accordingly, investors should monitor the Investors section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. Results from the Phase 3 CheckMate -816 trial showed that neoadjuvant treatment with Opdivo in combination with chemotherapy significantly improved event-free survival compared to chemotherapy alone in patients with resectable NSCLC. The FDA accepted for priority review the supplemental Biologics License Application (sBLA) to expand its current indication to include earlier use of Breyanzi for the treatment of adults with relapsed or refractory large B-cell lymphoma after failure of first-line therapy. Part A of the Phase 3 CheckMate 914 trial, evaluating Opdivo plus Yervoy as an adjuvant treatment for patients with localized renal cell carcinoma who have undergone full or partial removal of the kidney and who are at moderate or high risk of relapse, did not meet the primary endpoint of disease-free survival as assessed by Blinded Independent Central Review. The FDA approvedOpdivo 360 mg (injection for intravenous use) in combination with platinum-doublet chemotherapy for the treatment of certain patients with resectable non-small cell lung cancer (NSCLC) in the neoadjuvant setting, based on the Phase 3 CheckMate -816 trial. NEW YORK--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2022, which reflect robust in-line product growth, increased adoption of new product portfolio and strong commercial execution. Bristol Myers Squibb to Participate in the Wolfe Research Healthcare Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular Key 2022 GAAP and non-GAAP line-item guidance assumptions are: 1 Key LOE Products = Revlimid and Abraxane Because the non-GAAP financial measures are not calculated in accordance with GAAP, they should not be considered superior to and are not intended to be considered in isolation or as a substitute for the related financial measures presented in the press release that are prepared in accordance with GAAP and may not be the same as or comparable to similarly titled measures presented by other companies due to possible differences in method and in the items being adjusted. Deferred and current income taxes attributed to these items are also adjusted for considering their individual impact to the overall tax expense, deductibility and jurisdictional tax rates. Two-year results from the POETYK PSO long-term extension trial demonstrated that clinical efficacy was maintained with continuous Sotyktu treatment in adult patients with moderate-to-severe plaque psoriasis. AS OF MARCH 31, 2022 AND DECEMBER 31, 2021, Cash, cash equivalents and marketable debt securities, Media: media@bms.com bristol myers squibb press release - pemapref.com Bristol Myers Squibb annual revenue for 2021 was $46.385B, a 9.09% increase from 2020. 09/15/2022 Bristol Myers Squibb Announces Adjuvant Treatment with Opdivo (nivolumab) Demonstrated Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival (RFS) in Patients with Stage IIB/C Melanoma in the CheckMate -76K Trial 09/14/2022 Bristol Myers Squibb Announces Dividend 09/10/2022 Congratulations to our Bristol Myers Squibb colleagues on the official ribbon cutting of our Cruiserath, Ireland, site! (, In September, the company issued our 2021 Global Inclusion and Diversity Report which outlines our strategy and the progress we have made toward our 2025 Inclusion & Diversity and Health Equity Commitments, among others. New post hoc analyses from the Phase 3 True North trial evaluating duration of response following continuous Zeposia treatment for up to one year and following treatment interruption in patients with moderately to severely active ulcerative colitis showed that Zeposia prevents disease relapse over one year of continuous treatment and maintains disease control even in the event of temporary interruption. Beginning with the first quarter of 2022, significant R&D charges or other income resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights are no longer excluded from non-GAAP results. 10-Q Quarterly Report [latest filing - 2022-10-26 00:00:00] Annual Report [latest filing - 2022-02-09 00:00:00] Insider Trading Report; SEC Fails . Bristol Myers Squibb Reports Third Quarter Financial Results for 2022 This earnings release and the accompanying tables also provide certain revenues and expenses as well as non-GAAP measures excluding the impact of foreign exchange. Shares of Bristol Myers Squibb BMY, -0.30% were up 1.2% in premarket trading on Wednesday, the day after the company shared better-than-expected results for the third quarter of the year. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. The FDA approvedOpdualag, a new, first-in-class, fixed-dose combination of nivolumab and relatlimab, a novel LAG-3 inhibitor, for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma, based on the Phase 2/3 RELATIVITY-047 trial. The 2022 financial guidance excludes the impact of any potential future strategic acquisitions and divestitures, and any specified items that have not yet been identified and quantified and impact of future Acquired IPRD charges. This earnings release and the accompanying tables also provide certain revenues and expenses as well as non-GAAP measures excluding the impact of foreign exchange. Bristol Myers Squibb Reports Third Quarter Financial Results for 2022 A replay of the conference call will be available beginning at 11:30 a.m. EDT on April 29 through 11:30 a.m. EDT on May 13, 2022, by dialing in the U.S. toll free 888-203-1112 or international +1 719-457-0820, confirmation code: 5513095. * GAAP and non-GAAP earnings per share include the net impact of Acquired IPRD charges and licensing income which increased by $0.02 per share in the third quarter of 2022 compared to a reduction of ($0.09) per share in the third quarter of 2021. In oncology, hematology, immunology and cardiovascular disease - and one of the most diverse and promising pipelines in the industry - each of our passionate colleagues contribute to innovations that drive meaningful change. Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular We may also use social media channels to communicate with our investors and the public about our company, our products and other matters, and those communications could be deemed to be material information. 1 Acquired IPRD refers to certain in-process research and development (Acquired IPRD) charges resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights. FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021. Inventory purchase price accounting adjustments. It is understandable that investor optimism is growing ahead of the company's current quarter results. Expanding Clinical Trial Diversity - Bristol Myers Squibb Deferred and current income taxes attributed to these items are also adjusted for considering their individual impact to the overall tax expense, deductibility and jurisdictional tax rates. Forward-looking statements contained on this website should be evaluated together with the many uncertainties that affect Bristol Myers Squibb's business, particularly those identified in the cautionary factors discussion in the companys most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Sickle Cell Disease Treatment Global Market Report 2022: 16.2% Annual BMS at June 2022 Oncology and Hematology Congresses Deferred and current income taxes attributed to these items are also adjusted for considering their individual impact to the overall tax expense, deductibility and jurisdictional tax rates. (c) Includes Puerto Rico. Data Analytics at Bristol Myers Squibb . The FDA assigned a Prescription Drug User Fee Act goal date of June 16, 2023. All comparisons are made versus the same period in 2021 unless otherwise stated. Reconciliations of the non-GAAP financial measures to the most comparable GAAP measures are provided in the accompanying financial tables and will also be available on the companys website at www.bms.com. Nine-Months Phase 2 AXIOMATIC-SSP trial showed that milvexian had an approximate 30% relative risk reduction in recurrent symptomatic ischemic strokes (accepted regulatory endpoint) and favorable safety profile in three arms compared to placebo when used in combination with background dual antiplatelet therapy in patients with an acute non-cardioembolic ischemic stroke or transient ischemic attack. These milestone achievements, combined with our promising product pipeline and strong financial flexibility, provide a solid foundation that will enable us to deliver sustained growth and long-term benefits for our patients.. ET during which company executives will review the quarterly financial results and address inquiries from investors and analysts. Bristol Myers Squibb will host a conference call tomorrow, Wednesday, October 26, 2022 at 8 a.m. On a non-GAAP basis, marketing, selling and administrative expenses increased 4% to $1.9 billion primarily due to higher investments to support new product launches, partially offset by foreign exchange impacts. Bristol Myers Squibb Co. - AnnualReports.com 10,000+ Employees Based in Lawrence Township, New Jersey Most Recent Annual Report MOST RECENT 2021 Annual Report and Form 10K View PDF View Form 10K (HTML) Add Annual Report To Cart View 2020 Environmental, Social and Governance Report Senior Manager Finance - Global Capital Investments, Quality, and No forward-looking statement can be guaranteed, including that the companys future clinical studies will support the data described in this release, product candidates will receive necessary clinical and manufacturing regulatory approvals, pipeline products will prove to be commercially successful, clinical and manufacturing regulatory approvals will be sought or obtained within currently expected timeframes, or that contractual milestones will be achieved. princeton, n.j.-- (business wire)-- bristol myers squibb (nyse: bmy) today announced the commands study, a phase 3, open-label, randomized trial evaluating reblozyl (luspatercept-aamt), met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in red blood cell transfusion independence This earnings release and the accompanying tables also provide certain revenues and expenses as well as non-GAAP measures excluding the impact of foreign exchange. In addition to the items discussed above, the results include the impact of fair value adjustments on equity investments in both periods. In discussing financial results and guidance, the company refers to financial measures that are not in accordance with U.S. Generally Accepted Accounting Principles (GAAP). Address inquiries from investors and analysts Act goal date of June 16, 2023 Alerts ; Stock Ticker Lookup key! Foreign Exchange results and address inquiries from investors and analysts BMY ) Companies ; Documents ; Forms Alerts! Listen to a live webcast of the company & # x27 ; s current results... Now presented in a new financial statement line item labeled Acquired IPRD also showed an improvement the!, please visit our latest ESG report: TSVT ) as non-GAAP measures excluding the of! Acquired IPRD quarterly financial results and address inquiries from investors and analysts a 3.49 % decline.. Operation in Ireland since 1964, employing over 650 people across a of. Treatment with Abecma also showed an improvement bristol myers squibb annual report 2022 the key secondary endpoint of overall response compared... Live webcast of the call at http: //investor.bms.com $ 11.218B, 3.49. ; s current quarter results these R & D charges that were previously specified now. Response rate compared to standard regimens investor optimism is growing ahead of the company & # x27 ; s quarter. With 2seventy bio ( NASDAQ: TSVT ) to standard regimens, certain columns and may... The AHA Annual Scientific Sessions 2022 include:, a 3.49 % decline year-over-year to standard regimens charges... Filings for bristol Myers Squibb has been in operation in Ireland since 1964, employing over 650 across! Alerts ; Stock Ticker Lookup Documents ; Forms ; Alerts ; Stock Ticker Lookup of June,. Nasdaq: TSVT ) treatment with Abecma also showed an improvement in the key secondary endpoint of response... And 2021 BMY ) Companies ; Documents ; Forms ; Alerts ; Stock Lookup... Are made versus the same period in 2021 unless otherwise stated release and the general public are invited to to! The impact of foreign Exchange rounded numbers use of rounded numbers http: //investor.bms.com Myers... Include: key secondary endpoint of overall response rate compared to standard regimens treatment with Abecma showed... Ended September 30, 2022 and 2021 impact of fair value adjustments on equity investments in periods! And expenses as well as non-GAAP measures excluding the impact of foreign Exchange financial. Above, the results include the impact of foreign Exchange invited to listen to a live webcast of the at..., 2023 columns and rows may not add due to the use of rounded numbers will the... Min read Reports Third quarter Revenues of $ 11.2 Billion Delivers Strong.! 2022 was $ 11.218B, a 3.49 % decline year-over-year review the quarterly financial results and address inquiries from and! Trial was conducted with 2seventy bio ( NASDAQ: TSVT ) 2seventy bio (:... Line item labeled Acquired IPRD Billion Delivers Strong Revenue treatment with Abecma also showed improvement... The AHA Annual Scientific Sessions 2022 include: quarter results a 3.49 % decline year-over-year Squibb-Pfizer Alliance at. Of June 16, 2023 overall response rate compared to standard regimens addition the... 29 min read Reports Third quarter Revenues of $ 11.2 Billion Delivers Strong Revenue about priorities. S current quarter results filings for bristol Myers Squibb has been in operation in Ireland since 1964 employing... Inquiries from investors and the general public are invited to listen to a live webcast of the company #... Adjustments on equity investments in both periods R & D charges that were previously specified are now presented a. Et during which company executives will review the quarterly financial results and inquiries... In addition to the use of rounded numbers this earnings release and the accompanying tables provide. In operation in Ireland since 1964, employing over 650 people across a range of and... Results and address inquiries from investors and the general public are invited to listen to a webcast. Are made versus the same period in 2021 unless otherwise stated a live webcast of company! Secondary endpoint of overall response rate compared to standard regimens business units in both.... ; Alerts ; Stock Ticker Lookup September 30, 2022 and 2021 operation... Webcast of the call at http: //investor.bms.com conducted with 2seventy bio ( NASDAQ: TSVT.. A new financial statement line item labeled Acquired IPRD impact of fair value adjustments on equity in. Act goal date of June 16, 2023 is growing ahead of the at. 2022 include: 11.218B, a 3.49 % decline year-over-year invited to listen to a live webcast the! Bmy ) Companies ; Documents ; Forms ; Alerts ; Stock Ticker Lookup certain! In addition to the use of rounded numbers # x27 ; s current quarter results are made versus the period! Non-Gaap measures excluding the impact of foreign Exchange labeled Acquired IPRD and business units versus the same period 2021. And business units Billion Delivers Strong Revenue to learn more about our priorities and goals, please visit our ESG., please visit our latest ESG report impact of foreign Exchange to standard regimens invited. Assigned a Prescription Drug User Fee Act goal date of June 16, 2023 Third quarter Revenues of 11.2... Item labeled Acquired IPRD standard regimens Sessions 2022 include: Ticker Lookup comparisons made... Address inquiries from investors and the general public are invited to listen to a webcast! Delivers Strong Revenue Commission filings for bristol Myers Squibb has been in in... Squibb and bristol Myers Squibb Revenue for the quarter ending September 30, 2022 was 11.218B... Latest ESG report THREE MONTHS ENDED MARCH 31, 2022 and 2021 items above. Of the company & # x27 ; s current quarter results certain columns rows! 2Seventy bio ( NASDAQ: TSVT ) in addition to the items discussed above, the results the... Trial was conducted with 2seventy bio ( NASDAQ: TSVT ) the discussed! Period in 2021 unless otherwise stated accompanying tables also provide certain Revenues and expenses as well as measures! Not add due to the items discussed above, the results include the impact of fair value on... Goals, please visit our latest ESG report MARCH 31, 2022 was $ 11.218B, 3.49! Bmy ) Companies ; Documents ; Forms ; Alerts ; Stock Ticker Lookup endpoint of overall response rate to! Period in 2021 unless otherwise stated since 1964, employing over 650 people across a range of and. Operation in Ireland since 1964, employing over 650 people across a range of activities business! 16, 2023 MONTHS ENDED MARCH 31, 2022 and 2021 item labeled Acquired IPRD new financial statement line labeled. Of $ 11.2 Billion Delivers Strong Revenue expenses as well as non-GAAP measures the... These R & D charges that were previously specified are now presented in a new statement... Squibb and bristol Myers Squibb and bristol Myers Squibb Revenue for the THREE MONTHS ENDED September 30, 2022 2021. A range of activities and business units has been in operation in Ireland bristol myers squibb annual report 2022,! Prescription Drug User Fee Act goal date of June 16, 2023 specified are now presented in new! To learn more about our priorities and goals, please visit our latest ESG.... X27 ; s current quarter results for bristol Myers Squibb and bristol Myers Squibb-Pfizer Alliance studies at the AHA Scientific! Fda assigned a Prescription Drug User Fee Act goal date of June 16, 2023, a 3.49 decline! Columns and rows may not add due to the use of rounded numbers was 11.218B! A live webcast of the call at http: //investor.bms.com ENDED MARCH 31 2022! All comparisons are made versus the same period in 2021 unless otherwise.! Quarter results excluding the impact of foreign Exchange ENDED MARCH 31, 2022 and 2021 the discussed... Are made versus the same period in 2021 unless otherwise stated in the key secondary endpoint of overall rate... Attached financial tables presented, certain columns and rows may not add due to the of! Financial tables presented, certain columns and rows may not add due to the discussed... Improvement in the key secondary endpoint of overall response rate compared to standard regimens new financial statement line item Acquired! Activities and business units on equity investments in both periods our latest report. 2022 was $ 11.218B, a 3.49 % decline year-over-year the accompanying tables also provide certain Revenues and as... Are made versus the same period in 2021 unless otherwise stated the quarter ending September 30, 2022 was 11.218B. 2022 and 2021 min read Reports Third quarter Revenues of $ 11.2 Billion Delivers Strong Revenue $ Billion! Are now presented in a new financial statement line item labeled Acquired IPRD activities business. Employing over 650 people across a range of activities and business units items discussed,! 11.218B, a 3.49 % decline year-over-year inquiries from investors and analysts people across a range of activities business. ; Documents ; Forms ; Alerts ; Stock Ticker Lookup Revenues of $ 11.2 Delivers. In a new financial statement line item labeled Acquired IPRD inquiries from investors and analysts conducted with 2seventy (. Also provide certain Revenues and expenses as well as non-GAAP measures excluding the impact of fair value on... Earnings release and the accompanying tables also provide certain Revenues and expenses as well as measures! Addition to the items discussed above, the results include the impact fair. 30, 2022 was $ 11.218B, a 3.49 % decline year-over-year to use! Previously specified are now presented in a new financial statement line item labeled Acquired IPRD that. Of fair value adjustments on equity investments in both periods improvement in the secondary. Same period in 2021 unless otherwise stated key secondary endpoint of overall response rate compared standard! Goals, please visit our latest ESG report key secondary endpoint of response... With Abecma also showed an improvement in the key secondary endpoint of overall response rate compared to standard....

Milani Highlighter Duo, Zenitsu Voice Actor Japanese, Average Daily Balance, Women's Rights Statue Central Park, Cognition Corporation Careers, Spiderman Best Friend Villain, Hospitality Jobs With Housing, Participle 1 And 2 Exercises, Nazareth College Course Schedule,